Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201310119 Principal Investigator: Morgensztern, Daniel
Title: An open-label, multi-center, Expanded Treatment Protocol (ETP) of oral LDK378 in adult patients with non-small cell lung cancer (NSCLC) characterized by ALK(+) rearrangements in patients previously treated with an ALK inhibitor
Phase: N/A Disease Site: Lung
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this research is to find out if the drug LDK378 is safe and has beneficial effects in people who have ALK positive NSCLC.
 
More Information:
ClinicalTrials.Gov Link
Internal Protocol Documents (requires Siteman administrative database password)